Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.75
Bid: 13.50
Ask: 14.00
Change: 0.00 (0.00%)
Spread: 0.50 (3.704%)
Open: 13.75
High: 13.75
Low: 13.75
Prev. Close: 13.75
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Stocks up ahead of US nonfarm payrolls

Thu, 04th Jan 2024 16:54

(Alliance News) - Stock prices in London closed higher on Thursday, as investors eye the latest US non-farms data.

The FTSE 100 index closed up 40.74 points, 0.5%, at 7,723.07. The FTSE 250 ended up 45.65 points, 0.2%, at 19,372.05, and the AIM All-Share closed up 1.79 points, or 0.2%, at 755.94.

The Cboe UK 100 ended up 0.6% at 771.71, the Cboe UK 250 closed up 0.6% at 16,874.97, and the Cboe Small Companies ended up 0.5% at 14,940.05.

Stocks in New York were higher at the London equities close, with the DJIA up 0.7%, the S&P 500 index up 0.4%, and the Nasdaq Composite up 0.2%.

Since the new year, eyes have been on the US economy and where interest rates may go in 2024.

On Wednesday evening, investors had the minutes from the latest US Federal Reserve meeting, back in December.

At the December meeting, the rate-setting Federal Open Market Committee agreed to hold its benchmark rate steady in a range between 5.25% and 5.5%. Members indicated that they expect three quarter-percentage point cuts by the end of 2024.

"In discussing the policy outlook, participants viewed the policy rate as likely at or near its peak for this tightening cycle, though they noted that the actual policy path will depend on how the economy evolves," the highly anticipated minutes stated.

Officials "reaffirmed that it would be appropriate for policy to remain at a restrictive stance for some time until inflation was clearly moving down sustainably."

On Thursday, focus has been on the health of the US labour market.

The US labour market added more jobs than expected in December, according to a tracker from payroll processing firm ADP.

ADP said sector employment increased by 164,000 jobs in December, picking up from a 101,000 rise in November and ahead of the FXStreet cited consensus of 115,000. The November total of jobs added was revised from 103,000 to 101,000.

Meanwhile, US new jobless claims fell by more than expected in the most recent week.

According to the US Department of Labor, new jobless claims totalled 202,000 in the week ended December 30. This is down from last week's revised level of 220,000. The latest reading came in lower than FXStreet-cited consensus of 216,000.

The data is out ahead of the US nonfarm payrolls Friday.

Meanwhile, in European equities on Thursday, the CAC 40 in Paris and the DAX 40 in Frankfurt both ended up 0.5%.

According to Destatis, Germany's annual inflation picked up to 3.7%, from 3.2% in November. This came in slightly behind FXStreet market consensus of 3.8%.

Capital Economics' Andrew Kenningham commented: "The jump in Germany's headline inflation rate in December came as no surprise as it was driven by energy price subsidies introduced more than a year ago. With core inflation continuing to trend down, it should not affect investors' expectations for the [European Central Bank] to begin cutting interest rates in the coming months."

The pound was quoted at USD1.2696 at the London equities close Thursday, up compared to USD1.2646 at the close on Wednesday. The euro stood at USD1.0961 at the European equities close Thursday, higher against USD1.0915 at the same time on Wednesday. Against the yen, the dollar was trading at JPY144.48, up compared to JPY143.50 late Wednesday.

In the FTSE 100, retailers Next and JD Sports were the best and worst performing blue-chip stocks respectively, after both provided trading updates including the Christmas period.

JD Sports Fashion plummeted 23%, after cutting its profit outlook amid weaker-than-expected sales growth and gross margins.

The retailer said organic revenue was up 6.0% in the 22 weeks that ended December 30 on a constant currency basis from a year earlier, with like-for-like growth of 1.8%. This was slightly behind its expectations. The retailer expects organic revenue growth of around 8% for the year ending February 3.

As a result, it expects to report pretax profit and adjusted items of between GBP915 million and GBP935 million for the financial year. This falls short of market expectations of GBP1.04 billion, which back in September, JD Sports had said it expected to meet.

Next rose 5.5%, on the back of its trading update.

"Clothing retailer Next has set the bar high for the rest of the retail sector by posting a strong trading update this morning," Edison analyst Russell Pointon commented.

In the nine weeks to December 30, the clothing and homewares seller's full price sales were 5.7% higher year-on-year, some GBP38 million better than its previous guidance. It had expected growth of 2.0% year-on-year. The period forms part of its fourth quarter, which concludes on January 27.

The company now expects pretax profit for financial 2024 of GBP905 million, a lift of GBP20 million from its previous outlook, and it would represent a year-on-year increase of 4.0%. Next had initially expected pretax profit of GBP795 million, but it has, now on a number of occasions, lifted its bottom line outlook.

Meanwhile, BP and Shell rose 0.5% and 0.2%, respectively, as oil prices extended their recent upward movements on concerns over the Middle East.

"The region remains a tinder box due to the Israel-Gaza war, and disruption to shipping routes through the Red Sea is also a key factor behind the surge in crude," AJ Bell's investment director Russ Mould explained.

Brent oil was quoted at USD76.60 a barrel at the London equities close Thursday, down from USD78.13 late Wednesday. Over the last week the price has hit highs of USD79.83.

On London's AIM, Angle shares more than doubled to 31.40 pence.

The Surrey-based medical diagnostics provider celebrated "breakthrough results" from its latest blood sample cancer trials would allow it to expand its product sales and pharma services.

Gold was quoted at USD2,0445.01 an ounce at the London equities close Thursday, up against USD2,038.89 at the close on Wednesday.

In Friday's UK corporate calendar, MTI Wireless Edge will hold its extraordinary general meeting regarding proposed grant of options to the directors.

The economic calendar for Friday has eurozone inflation readings at 1000 GMT. Before that, there is the UK Halifax house price index at 0700 GMT.

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
7 Mar 2019 09:35

Angle completes enrolment in Parsortix breast cancer study

(Sharecast News) - Liquid biopsy company Angle announced on Thursday that enrolment for its 'Parsortix' FDA clinical study for metastatic breast cancer was now complete.

Read more
28 Feb 2019 13:30

Angle Enrolls First Patients In Ovarian Cancer Study

LONDON (Alliance News) - Angle PLC on Thursday said it has enrolled the first patients in an ovarian cancer verification study, after receiving ethics approval.The study will be divided a a

Read more
25 Feb 2019 10:51

Angle client demonstrates new use for 'Parsortix' system

(Sharecast News) - Liquid biopsy company Angle said on Monday that one of its leading customers, the Disseminated Cancer Cell Network (DCCNet) in Duesseldorf, has published new results in a peer-reviewed journal of work done to harvest circulating tumor cells (CTCs) from diagnostic leukapheresis (DLA) samples.

Read more
11 Feb 2019 11:35

Angle's 'Parsortix' used in new groundbreaking cancer research

(Sharecast News) - Liquid biopsy company Angle announced on Monday that its 'Parsortix' system had been utilised in further "groundbreaking" cancer research into CTC clusters, reportedly demonstrating that the patient's own immune cells (neutrophils) could actively help the process of metastasis by which the cancer spread.

Read more
31 Jan 2019 12:04

Angle Reports Widened Interim Loss On Higher Operating Costs

LONDON (Alliance News) - Angle PLC on Thursday reported a widened interim loss on an increase operating costs.In the six months to October 31, the tumour cell researcher said its pretax to

Read more
24 Jan 2019 15:58

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 25 January BonmarcheTrading Statement AG BarrTrading GroupQ3 Smaller

Read more
10 Jan 2019 17:05

Angle Shares Jump As Parsortix System Used In New Cancer Treatment

LONDON (Alliance News) - Angle PLC shares spiked late Thursday afternoon after the company said its Partsortix system will be used in "ground-breaking" new cancer research.Shares

Read more
5 Nov 2018 12:11

ANGLE To Acquire Remaining Stake In US Subsidiary For GBP467,500 (ALLISS)

LONDON (Alliance News) - Liquid biopsy company ANGLE PLC said on Monday it has agreed to acquire the remaining shares in US subsidiary ANGLE North America Inc it does not own from Parsotix Georgi

Read more
1 Nov 2018 14:09

Angle Appoints Cancer Diagnostic Firm Chief As Non-Executive Director

LONDON (Alliance News) - Biopsy company Angle PLC said Thursday it has appointed the President of Euronext-listed cancer diagnostics firm MDxHealth to its board.Jan Groen joins the board of

Read more
29 Oct 2018 11:27

Angle Pilot Study Shows Promise Of Parsortix In Prenatal Testing

LONDON (Alliance News) - Liquid biopsy company Angle PLC on Monday said it has received positive results from a study examining the use of its Parsortix system in prenatal testing.Shares in

Read more
29 Oct 2018 11:08

Angle sees 'highly encouraging' results from prenatal testing

(Sharecast News) - Medical diagnostics outfit Angle is talking to "several interested parties" to commercialise its testing device after a "highly encouraging" trial indicated it could be adapted as a non-invasive prenatal test.

Read more
25 Oct 2018 12:55

Angle Nearing Completion Of Patient Enrolment Breast Cancer Study

LONDON (Alliance News) - Liquid biopsy firm Angle PLC said it is making good progress on recruiting patients for its ANG-002 clinical study.The study is focusing on a treatment for breast a

Read more
25 Oct 2018 08:52

Angle makes 'good progress' with ANG-002 patient enrolment

(Sharecast News) - Liquid biopsy company Angle announced on Thursday that patient enrolment for its ANG-002 FDA clinical study for metastatic breast cancer had continued to make good progress.

Read more
23 Oct 2018 15:59

UK Shareholder Meetings Calendar - Next 7 Days

Wednesday 24 OctoberIndigovisionBeeks FinancialReddePhoto-Me 25 & Smart 26 29 30

Read more
28 Aug 2018 14:17

Angle's Parsortix System Able To Identify Tumour Cells In Glioblastoma

LONDON (Alliance News) - Angle PLC on Tuesday said researchers at the Cancer Metastasis Laboratory, located at the University of Basel, have provided evidence of circulating tumour cell clusters a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.